6-K

UNITED STATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of February 2023

Commission File Number: 001-31995

MEDICUREINC.

(Translation of registrant's name into English)

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

EXHIBITLIST

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS

WINNIPEG, MB, Feb. 1, 2023 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.

"On behalf of the Board and senior leadership team, I would like to thank Gerry for his long-standing years of service to the Company, stated Albert Friesen," Chair of Medicure's Board of Directors.  "His experienced guidance and reasoned strategic insights greatly benefited Medicure throughout the years and we were blessed to have someone of Gerry's character and integrity in a governance position."

The Company also announces that it has granted stock options (the "Options") to certain directors, officers and employees of the Company to purchase a total of 1,205,000 common shares at a price of $1.25 per common share. The Options are exercisable for a period of ten years and have been granted in accordance with the terms of the Company's current stock option plan. The grant of Options is subject to the approval of the TSX Venture Exchange.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^®^ (tirofiban hydrochloride) injection and ZYPITAMAG^®^ (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug^®^ is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT^®^, please visit www.aggrastathdb.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG^®^, please visit www.zypitamag.com or refer to the full Prescribing Information.

To be added to Medicure's e-mail list, please visit:     http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracyof this release.

Forward Looking Information: Statements containedin this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes","may", "plans", "will", "estimates", "continues", "anticipates", "intends","expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadianand U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referredto as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of theCompany made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factorswhich the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknownrisks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events ordevelopments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements,and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others,the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority reviewvoucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capitalrequirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company'sproducts, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation orregulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions whichmay prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changesin Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatoryand governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercialoperations and/or research and development projects, or the availability of financing on reasonable terms; results of current and futureclinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing listof important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise anyforward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussionregarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicableCanadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section ofits Form 20F for the year ended December 31, 2021.

AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.

View original content:https://www.prnewswire.com/news-releases/medicure-announces-resignation-of-board-member-and-grant-of-stock-options-301735795.html

SOURCE Medicure Inc.

View original content: http://www.newswire.ca/en/releases/archive/February2023/01/c4073.html

%CIK: 0001133519

For further information: Please contact: Dr. Albert Dr. Friesen, Chief Executive Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com

CO: Medicure Inc.

CNW 07:00e 01-FEB-23